OP Asset Management Ltd Makes New $3.49 Million Investment in Teladoc Health, Inc. $TDOC

OP Asset Management Ltd purchased a new stake in Teladoc Health, Inc. (NYSE:TDOC) during the first quarter, HoldingsChannel.com reports. The fund purchased 639,900 shares of the health services provider’s stock, valued at approximately $3,487,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Corient Private Wealth LLC raised its holdings in shares of Teladoc Health by 236.6% during the fourth quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock worth $264,000 after acquiring an additional 26,494 shares during the period. Alpine Global Management LLC acquired a new position in Teladoc Health in the 4th quarter worth $187,000. Virtu Financial LLC bought a new position in Teladoc Health during the 4th quarter worth about $854,000. Mackenzie Financial Corp increased its holdings in Teladoc Health by 38.6% during the 4th quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock worth $1,157,000 after purchasing an additional 46,090 shares in the last quarter. Finally, Empowered Funds LLC raised its stake in shares of Teladoc Health by 1.9% in the 4th quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock valued at $5,196,000 after purchasing an additional 14,029 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Trading Up 5.7%

Teladoc Health stock opened at $8.36 on Friday. The firm has a 50-day moving average of $6.89 and a 200-day moving average of $6.25. Teladoc Health, Inc. has a one year low of $4.40 and a one year high of $9.77. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -8.62 and a beta of 2.14.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The company had revenue of $613.85 million during the quarter, compared to the consensus estimate of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. Teladoc Health’s revenue was down 2.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.53) EPS. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, equities analysts expect that Teladoc Health, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teladoc Health news, insider Adam C. Vandervoort sold 7,906 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the transaction, the insider directly owned 110,261 shares in the company, valued at $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $47,275.48. Following the transaction, the insider directly owned 57,671 shares in the company, valued at $440,029.73. This trade represents a 9.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 39,870 shares of company stock valued at $302,507 in the last ninety days. 0.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Oppenheimer cut their price target on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, March 3rd. Barclays dropped their target price on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 26th. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. JPMorgan Chase & Co. reduced their price target on Teladoc Health from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday, March 13th. Finally, Citigroup raised their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $7.43.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.